Clinical trials · Texas
Non Small Cell Lung Cancer Metastatic clinical trials in Texas
We’re tracking 191 recruiting non small cell lung cancer metastatic studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Dallas, TexasAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Kingwood, TexasAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Austin, TexasAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Dallas, TexasAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Round Rock, TexasAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Austin, TexasAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
San Antonio, TexasAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Houston, TexasAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Dallas, TexasAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Houston, TexasAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
San Antonio, TexasAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Houston, TexasAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
San Antonio, TexasAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
San Antonio, TexasAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Abilene, TexasAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
The Woodlands, TexasAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Houston, TexasAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
San Antonio, TexasAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Amarillo, TexasAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Lubbock, TexasAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Austin, TexasAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Dallas, TexasAges 18 years+
Non Small Cell Lung Cancer Metastatic trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting non small cell lung cancer metastatic studies listed above.
- The University of Texas MD Anderson Cancer Center · 13 studies
- Community Clinical Trials · 3 studies
- NEXT Oncology · 3 studies
- Renovatio Clinical · 3 studies
- Research Site · 3 studies
- JPS Health Network · 2 studies
- Mary Crowley Cancer Research · 2 studies
- Texas Oncology - Northeast Texas · 2 studies
What taking part in a non small cell lung cancer metastatic study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Non Small Cell Lung Cancer Metastatic trials in other states
Common questions
- Are there non small cell lung cancer metastatic clinical trials in Texas?
- Yes. We're currently tracking 191 recruiting non small cell lung cancer metastatic studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer metastatic study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer metastatic studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.